Nasal Type Extranodal NK/T-Cell Lymphoma

Nasal Type Extranodal NK/T-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 25
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 16%
Top sponsor: Ruijin Hospital
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05131438	An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)	no longer available	—	—	EQRx International, Inc.INDUSTRY	1	Mar 27, 2023	clinicaltrials

Data updated 22 days agoSource updated Mar 27, 2023source: clinicaltrials